u/marit_sandvik

handlers in the community are rare and cautious

What was the trial arm you are quoting from? SURMOUNT-1, -2, -3 are all different.

Edit to your parent would help — the concentration you quoted assumes one scenario and you have written another above it.

private prescription routes vary by region

the 15mg is the top of the pen, not the required dose

Small correction: the trial was 21 weeks, not 3. Does not change your point but people will quote it.

the appetite change on tirz is more than just reduced hunger, it is different machinery

Dead space in the needle hub holds a small but non-trivial volume. On low-volume draws that can be several units.

Disagree but this is the good kind of wrong — it is specific enough to be checked.

Correct. The batch number is load-bearing information, not optional.

oral non-peptide agonist is ACHIEVE, no food restrictions

Boots stock is hit-and-miss by location

Private pharmacy pricing in Spain: 2.5mg was tier 3 this month, 2% up from last month.

stalled on sema, tried tirz, and the curves were actually different shapes

Strongly agree. MHRA is region-specific.

Edit to your parent would help — the concentration you quoted assumes one scenario and you have written another above it.

This is correct. The naming is genuinely confusing.

This is the "correlation is mechanism" thing again. You changed three variables at once.

Strongly agree. MHRA is region-specific.